Previous studies reported that expression levels of LGI3 were decreased in cases of glioma and non-small cell lung cancer (NSCLC).[16–18] In this study, analysis of the DEGs in the pancreas tissues taken from PAC patients showed that LGI3 expression in tumor tissues was significantly lower than in healthy tissue (FC, fold change; FC = 0.70, P = 1.23 × 10−7 in GSE15471; FC = 0.91, P = 3.6 × 10−2 in GSE16515; FC = 0.85, P = 4.82 × 10−5 in GSE28735; FC = 0.83, P = 1.20 × 10−6 in GSE62452; FC = 0.88, P = 1.37 × 10−13 in GSE77858; FC = 0.89, P = 4.48 × 10−2 in GSE71729) (Fig. 1). Here, LGI3 is linked to central nervous system cancer.